Ser-884 Adjacent to the LXXLL Motif of Coactivator TRBP Defines Selectivity for ERs and TRs
Lan Ko,
Guemalli R. Cardona,
Toshiharu Iwasaki,
Kelli S. Bramlett,
Thomas P. Burris and
William W. Chin
Lilly Research Laboratories, Department of Gene Regulation, Bone
and Inflammation Research, Eli Lilly & Co.,
Indianapolis,
Indiana 46285
Address all correspondence and requests for reprints to: Dr. Lan Ko, Department of Gene Regulation, Bone & Inflammation Research, Lilly Corporate Center, Building 98/C, Drop Code 0434, Indianapolis, Indiana 46285. E-mail: kol{at}lilly.com
 |
ABSTRACT
|
---|
Ligand-dependent interaction of nuclear receptors and coactivators
is a critical step in nuclear receptor-mediated transcriptional
regulation. TR-binding protein (TRBP) interacts with nuclear receptors
through a single LXXLL motif. Evidence suggested that the sequences
flanking the LXXLL motif in a number of coactivators determine receptor
selectivity. We performed mutagenesis studies at residues adjacent to
the TRBP LXXLL motif and identified S884 of TRBP at the -3 position of
the LXXLL motif as a key residue for receptor selectivity. Analysis of
in vitro and in vivo receptor
interactions with TRBP suggested that S884 allowed selective
interactions for ERß, TR, and RXR vs. ER
. Transient
transfection studies further confirmed that the LXXLL-binding affinity
correlates with TRBP transcriptional activity. Consistent with the
structural modeling, an E380G substitution within ER
altered the
binding to TRBP mutants, demonstrating the direct contact between TRBP
S884 and ER
E380, which is a residue that distinguishes receptor
subclasses. Furthermore, S884 can be phosphorylated by MAPK in
vitro, an event that significantly altered the binding of TRBP
to ER and suggests a potential mechanism for regulatory interaction. As
the differential recruitment of TRBP to ER
and ERß may rely on
S884, our finding provides insight into estrogen signaling and may lead
to the development of therapeutic receptor-selective peptide
antagonists.
 |
INTRODUCTION
|
---|
HORMONE-INDUCED GENE ACTIVATION mediated by
nuclear receptors underlies many biological events such as cell
proliferation, differentiation, reproduction, and development
(1, 2, 3). Ligand-dependent interaction between nuclear
receptors and their cofactors is a critical step required for gene
activation. Previous biochemical and structural studies of many nuclear
receptors indicate that the ligand-dependent interaction of the
receptor with coactivators relies on the positioning of helix 12
located at the extreme carboxyl terminus of the conserved
ligand-binding domain (LBD) (4, 5). Ligand binding induces
a conformational change within the receptors that enables dissociation
of corepressors and association with coactivators (6, 7, 8).
A common LXXLL motif present in a number of coactivator molecules is
necessary and sufficient to mediate the interactions between the
coactivator and the nuclear receptor LBD (9, 10). The
most extensively characterized LXXLL-containing coactivators are the
three members of the SRC-1 family (11), SRC-1/NcoA-1
(12), TIF-2/GRIP-1/NcoA-2 (13, 14, 15), and
pCIP/AIB-1/TRAM-1/ACTR/RAC-3 (16, 17, 18, 19, 20, 21). Other
coactivators also possess LXXLL motifs and include CBP/p300
(22), PGC-1 (23, 24), CIA (25),
RIP140 (26), and DRIP205/TRAP220/PBP
(27, 28, 29). TRBP/ASC-2/RAP250/PRIP/NRC/AIB3
(30, 31, 32, 33, 34, 35) is another recently characterized coactivator
that has a single functional LXXLL motif.
Crystal structures of the LBD of many nuclear receptors have been
resolved (36, 37, 38, 39, 40, 41). The coactivator LXXLL motif binding
site of ligand-bound ER
is a shallow hydrophobic groove on the
surface of the LBD primarily formed by helices 3, 4, 5, and
12 (36). In antagonist-bound ER
, the
coactivator-binding groove is obscured by unique positioning of helix
12. Alignment of helix 12 in a number of nuclear receptors with many
coactivator LXXLL peptides revealed that the hydrophobic residues in
helix 12 closely resemble the leucines in the LXXLL and appear to mimic
functionally the LXXLL motif of the coactivator (37).
Thus, helix 12 functions as an autoinhibitory peptide for
antagonist-bound nuclear receptors.
It has been shown that the distinct LXXLL motifs display varying
degrees of nuclear receptor selectivity, which appear to be specified
by the amino acid residues immediately flanking the LXXLL motifs
(42, 43, 44, 45, 46, 47). The biological significance of selective
interactions between various nuclear receptors and coactivators is
still largely unclear; however, selective interaction in
vivo may play a role in tissue- and cell-specific effects
(48). In this regard, characterization of the mechanism(s)
of coactivator selectivity is important for understanding coactivator
function in nuclear receptor-mediated gene regulation.
The coactivator TRBP has been shown to interact with a number of
nuclear receptors in a ligand-dependent manner and enhance nuclear
receptor-mediated transcriptional activation. TRBP is a high mol wt
(2,063 amino acids) coactivator that associates with both CBP/p300 and
the DRIP complexes (30, 31, 33). TRBP also
coactivates multiple transcription factors including AP-1 and
NF
B (30) and its gene has been demonstrated to be
amplified in human breast cancers (31, 35). An
RRM-containing coactivator CoAA was recently shown to interact
with the carboxyl terminus of TRBP (49). In addition, the
carboxyl terminus of TRBP has also been shown to interact with nuclear
DNA-dependent protein kinase and poly (ADP-ribose) polymerase
complexes that are implicated in transcriptional regulation
(30). Interestingly, a single LXXLL motif is required for
the interaction of TRBP with TR, RXR, ER, and many other receptors.
However, the relative selectivity of these interactions between TRBP
and these receptors has not been characterized. To define the residues
flanking the TRBP LXXLL motif responsible for nuclear receptor
selectivity, we performed random mutagenesis of specific amino acids at
positions predicted to contact the surface of the nuclear receptor LBD.
A mutation at S884 at the -3 position of the TRBP LXXLL motif was
identified as a residue with the ability to alter TRBPs selectivity
for ER
vs. ERß both in vitro and in
vivo. Mutations at this residue also dramatically increased TRBP
binding to TR and RXR. We also show that the binding activities of TRBP
mutants to nuclear receptors correlates with their transcriptional
coactivation activities. Our results suggest that the interaction of
nuclear receptors with TRBP can be selective and may be regulated.
 |
RESULTS
|
---|
Identification of S884 in TRBP for Its Role in Receptor Binding
Selectivity by Random Mutagenesis
We previously reported that the LXXLL motif of the TRBP
coactivator is necessary and sufficient for the interaction with TRß
in a strict ligand-dependent manner (30). In addition,
this interaction is also completely AF-2 dependent. Several
lines of evidence suggested that various LXXLL motifs in a number of
coactivators display receptor selectivity in which the sequences
flanking the LXXLL motif specify the degree of receptor selectivity
(42, 43, 46). Many of these studies were conducted using
small synthetic coactivator peptides for selective interaction with
receptor LBD. We considered the possibility that a larger natural
protein might be more physiologically relevant in this type of
selection, since the global protein conformation may be
influential.
To assess the importance of residues flanking the TRBP LXXLL motif in
determining receptor selectivity, we performed random mutagenesis of
TRBP (amino acids 714-1242) in which the -3, -4, +7, and +8 positions
near the LXXLL motif were mutated. These four residues were chosen
because the LXXLL motif is an
-helical structure in which the -3,
-4, +7, and +8 positions are most likely aligned in the same
orientation as the conserved hydrophobic leucines. Hence, they are
likely to have direct contact with the receptor LBD. Degenerate PCR
primers introduced mutations randomly at these four specific amino acid
positions, and each mutated clone was screened for in vitro
nuclear receptor binding activity.
As shown in Fig. 1A
, 36 mutated TRBP
(7141,242) clones were screened for binding of the encoded proteins
to the LBDs of TRß, RXR
, ER
, and ERß in the presence of their
respective ligands. Compared with the wild-type control, most of the
mutants displayed decreased binding, probably because of alteration of
the natural coactivator protein conformation. By calculation,
approximately 17% of the mutations would introduce stop codons and
fail to produce full-length proteins. This was detected by the lack of
an input band in the assay and was verified by sequencing of the
mutations (Figs. 1
and 2A
). Our interest
was primarily focused on the mutations that display increased binding
activity. Among the positive clones, clone 6 had a surprisingly
significant increase in binding to TR and RXR and also had marked
increased binding to ERß but dramatically decreased binding to ER
.
Interestingly, clone 33 had a similar pattern as clone 6, in that the
binding to TRß, RXR
, and ERß was selectively higher than ER
,
but to varying degrees. Sequence analysis of the clones revealed that a
tyrosine residue at position -3 contributed to selectivity of TRBP
binding of TRß, RXR
, and ERß vs. ER
(Fig. 2A
). In
particular, S884 at position -3 in clones 6 and 33 was replaced by a
tyrosine. By contrast, most other mutants reduced TRBP-receptor
interaction. Of note, clone 6 had the least number of alterations at
other amino acid positions (S884Y and T883S), suggesting that the S884
position may significantly contribute to selective receptor
binding.

View larger version (121K):
[in this window]
[in a new window]
|
Figure 1. Randomly Mutated TRBP Clones Interact with TRß,
RXR , ER , and ERß
A TRBP fragment (7141242) containing the LXXLL motif was
randomly mutated by PCR using degenerated primers that introduce
mutations at amino acid residues -3, -4, +7, and +8 relative to the
LXXLL motif. Thirty-six plasmids containing mutations were isolated,
and the proteins were [35S]-methionine-labeled by
in vitro translation. The GST-LBD fusion protein of each
of the nuclear receptors (TRß, RXR, ER , and ERß) was tested in
pull-down assays in the presence of 1 µM of cognate
ligand with the labeled TRBP proteins. Specific nuclear receptors are
indicated on the left. Clones are numbered and shown at
bottom of each panel. WT is wild-type TRBP protein. The
input lane indicates 10% of the total input. A missing band indicates
generation of a stop codon, which was verified by sequencing. The
amount of GST protein used in assays for each receptor was carefully
balanced.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Figure 2. The S884 Residue of TRBP Displays an Important Role
in Receptor Selectivity
A, Diagram of a TRBP LXXLL motif (882895) is shown. Full-length TRBP
with the LXXLL motif is depicted on top. The amino acids
of the LXXLL motif are depicted in bold in both
wild-type (WT) and mutant (Mut) TRBP. The bold Xs
represent any amino acids at mutated -3, -4, +7, and +8 positions.
Clones with mutated amino acids are shown; an asterisk
indicates a stop codon. B, A computationally engineered TRBP peptide
(882895) shows that that the side chain of S884
(red) has the same orientation as the leucines
(green) in the LXXLL motif. The side chain of S884 is
near that of L887.
|
|
A TRBP peptide was computer generated to obtain detailed structural
information of S884 at position -3 (Fig. 2B
). Relative to the LXXLL
motifs of other coactivators, the LXXLL motif of TRBP is unique. It
contains a leucine at -1 position and a proline at the -2 position.
Consistent with previous reports, these characteristics lead to greater
binding to TRß (44, 45). As shown in Fig. 2B
, the TRBP
LXXLL (882895) motif structure was adapted and computationally
engineered based on the structure of the PPAR
AF-2 helix, which
aligns with the coactivator LXXLL motifs and has a leucine at the -1
and a proline at the -2 positions (37). The orientation
of the side chain of S884 in TRBP, due to Pro885, was found to align
with an orientation similar to that of the other four hydrophobic
leucines, L886, L887, L890, and L891 (Fig. 2A
). The conformation of the
TRBP LXXLL motif suggested that S884 might be involved in receptor
binding, and this is consistent with our finding that mutation of S884
alters the binding of TRBP to the LBD.
S884Y Differentiates the Binding of TRBP with ER
and ERß,
TRß, and RXR
in Vitro
To verify our data obtained in the random
mutagenesis screen, the TRBP protein (7141,242) with a S884Y mutation
was tested in in vitro binding assays. Binding of fusion
proteins consisting of glutathione-S-transferase (GST) fused
to the LBDs of TRß, RXR
, ER
, and ERß to wild-type TRBP and
the S884Y mutant were compared in the presence and absence of each
cognate ligand (Fig. 3
). Consistent with
the observations from the screen, the S884Y mutant had a significant
increase in binding to TRß, RXR, and ERß, but decreased
binding to ER
. Notably, the increase was strictly ligand dependent
for TRß and RXR, while S884Y increased ERß ligand-independent
binding. These results confirm that the S884 position plays an
essential role in determining receptor selectivity in
vitro.

View larger version (23K):
[in this window]
[in a new window]
|
Figure 3. Tyrosine Substitution of TRBP S884 Alters Nuclear
Receptor Selectivity
Tyrosine mutation of S884 (S884Y) in TRBP fragment (7141242) was
compared with the wild-type (WT) for the binding of the nuclear
receptor LBDs. GST-LBDs of TRß, RXR, ER , and ERß were incubated
with [35S]methionine-labeled TRBP and S884Y mutant in the
presence and absence of 1 µM of each cognate ligand as
indicated. The bound protein was quantitated, and results are shown as
the mean values of triplicate determinations ± SE
values.
|
|
Similar experiments were performed with ER
and ERß using
various ER ligands including E2, diethylstilbestrol (DES), estriol,
genestein, LY 117018, 4- hydroxytamoxifen, and ICI 182,780. The
S884Y mutant of TRBP showed selective binding to ERß vs.
ER
, although it displayed different profiles with each ligand (Fig. 4
). In particular, the S884Y mutant
favored estriol-bound ERß over E2- and DES-bound ERß. This
selectivity for estriol was confirmed in transfection and peptide
binding assays. Genestein has been previously shown to exhibit
selectivity for ERß (50). The S884Y appeared to increase
genesteins selectivity for ERß over ER
, suggesting that the S884
residue may play a role in determining ER-coactivator complex
responsiveness to various ligands. All together, these data further
indicate that S884 plays an essential role in establishing TRBP-ER
isoform selectivity.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 4. S884Y Increases TRBP Binding Affinity for ERß,
But Not ER , in Vitro
Similar experiments were done as in Fig. 3 , except ER and ERß were
compared without (-) or with (+) different ER ligands: E2
(E2), DES, estriol (E3), genestein (Gen), LY
117018 (LY), 4-hydroxytamoxifen (OHT), and ICI 182,780 (ICI).
|
|
S884Y Mutation Differentiates the Binding of TRBP with ER
and
ERß in Vivo
To confirm the effects of the S884Y mutation observed in
vitro, we employed a mammalian two-hybrid assay using Gal4-TRBP
(795999) and ER
- or ERß LBD-VP16 fusions. The results suggest
that the S884Y mutation leads to increased binding of TRBP with ERß
and decreased binding with ER
(Fig. 5
). However, the ligand-independent
interaction with ERß was also significantly increased in the S884Y
mutant. The S884E mutant, which has a negatively charged side chain,
was not able to mimic the effect of the hydrophobic tyrosine and failed
to interact. Alanine mutations (LA) of the conserved leucines in the
LXXLL motif abolished TRBP interaction with the ER-LBD and was used as
a negative control. These data indicate that the S884Y mutant was also
able to display selective interaction with ER isoforms in a cellular
content.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 5. The S884Y Mutation Increases TRBP Binding Affinity
for ERß, But Not ER , in Vivo
The mammalian two-hybrid system was used to detect protein-protein
interactions in CV-1 cells. Plasmids encoding GAL-TRBP (WT) or its
mutations at S884 (S884Y, S884E) were cotransfected with ER -LBD-VP16
(top panel) or ERß-LBD-VP16 (bottom
panel) together with the Gal-luciferase reporter. Experiments
were performed without or with 100 nM E2 (E2)
or estriol (E3). S884Y and S884E are tyrosine and glutamic
acid substitutions at S884. LA represents alanine mutations at
conserved leucines in the LXXLL motif. Relative luciferase activities
were measured and shown as means of triplicate transfections ±
SE values.
|
|
TRBP LXXLL Peptides with S884 Mutations Display Selectivity for
ER
and ERß
Binding to ER
and ERß was further evaluated in the LXXLL
motif peptide binding assay utilizing synthetic TRBP peptides
(878896) mimicking the different mutations at the S884 position. In
this time-resolved fluorescence assay, synthetic TRBP LXXLL peptides
are fluorescent labeled and then assessed for their ability to bind to
recombinant ER
and ERß. Consistent with our previous data, the
S884Y mutation significantly increased the interaction with ERß but
not ER
(Fig. 6
). A negative charge at
S884 (S884E) abolished binding of TRBP to both ER
and ERß. A
positive charge at the same position (S884R) did not decrease, but
rather increased, TRBP peptide binding to ER. This effect was
particularly apparent for ER
. As expected, a peptide harboring
alanine mutations (LA) of the conserved leucines was not able to bind.
In agreement with previous binding assays using large TRBP fragments,
these findings using synthetic peptides suggest that the S884 of TRBP
is an important residue responsible for the selective interactions with
ER isoforms. The binding activity within the peptide-binding assay may
not be entirely consistent with the activity of the large TRBP protein
fragments. In fact, variations of efficacy and affinity profiles for
each receptor were observed using the various assays. However, S884 was
consistently demonstrated, both in in vitro and in
vivo assays, to play an important role in ER
vs.
ERß selectivity. These results indicate that the conformation of the
side chain of S884 may contribute to the binding affinities of TRBP for
ER
and ERß.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 6. Peptide Binding Analysis of S884 Mutations for
Altered ER Selectivity
Synthetic TRBP peptides (878896) and mutations at S884 were assayed
with full-length baculovirus-expressed ER (top panel)
and ERß (bottom panel) using a time-resolved
fluorescence assay as described in Materials and
Methods. Experiments were performed with various concentrations
of E2. Arginine, tyrosine, and glutamic acid mutations at S884 are
indicated. LA represents TRBP with alanine mutations at Leu890 and
Leu891, which was used as a negative control.
|
|
Transcriptional Activity of S884Y TRBP Correlates with Its Receptor
Binding Affinity
The S884Y mutation of TRBP selectively altered the binding to
nuclear receptors. This prompted us to examine whether the S884Y mutant
would also affect the transcriptional activity of TRBP. Since the C-
terminal region of TRBP possesses the major transcriptional
activation domain, the S884Y mutant of the TRBP C-terminal region
(7142063) was constructed and compared with the wild-type TRBP in
terms of their transcriptional activities. In transient transfection
assays, TRBP S884Y increased ligand-dependent ERß-mediated
transcription and decreased ligand- dependent ER
-mediated
transcription (Fig. 7
, A and B).
Consistent with our data suggesting that this mutation increased
ligand-independent interaction with ERß, the ligand-independent
transactivation mediated by ERß was also increased. In the case of
TRß, both thyroid hormone response element (F2)-reporter
activities mediated by TRß1 and Gal-reporter activity mediated by the
Gal4-TRß-LBD fusion protein were tested. In both cases, the
ligand-dependent activity was increased with the TRBP S884Y mutant
(Fig. 7
, C and D). Taken together, these results show that S884 affects
the selectivity of TRBP for nuclear receptor interaction, as well as
its coactivation potential.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 7. Transcriptional Activity of the Mutant TRBP at S884
Correlates with Its Binding Activity
A and B, Coactivation functions of wild-type TRBP (7142063)(WT),
S884Y mutant (S884Y), and vector control (V) were tested with 2XERE
luciferase reporters. CV-1 cells were transfected in 24-well plates
with 10 ng full-length ER or ERß, 200 ng TRBP or mutant, and 100
ng luciferase reporter. Cells were treated with or without 100
nM estriol (E3). Luciferase activity were
measured and data were shown as means of triplicate transfections
± SE values. C, Similar transfection as those in panels A
and B were performed except that the full-length TRß1 (10 ng) and
F2/TRE luciferase reporter (100 ng) were used, and 100 nM
T3 was used as ligand. D, A Gal-TRß-LBD fusion plasmid
(100 ng) and 5XGAL-luc reporter (100 ng) were used for transfection
together with 200 ng TRBP, mutant, or vector control. Other conditions
were the same as in panel C.
|
|
S884 Has Close Contact with Helix 4 of ER
at Glu380
Using computer modeling of the crystal structure of ER
, ERß,
and TRß with the TRBP LXXLL peptide, we obtained further structural
evidence for the role of the S884 position in determining the
interaction with the nuclear receptor LBD. The structure of the TRBP
LXXLL (882895) motif was engineered based on the PPAR
helix 12
(Fig. 2B
). The engineered TRBP peptide docking was carried out by
three-dimensional alignment with the TRBP peptide and the GRIP-1
peptide cocrystallized with ER
(36). The backbone and
the leucine residues within the LXXLL motif of GRIP-1 were aligned with
the backbone and the leucines within the TRBP LXXLL peptide. Side chain
orientations were adapted from PPAR
helix 12 (40). As a
result, the L887, L890, and L891 in TRBP LXXLL motif were found to
insert into the hydrophobic coactivator-binding pocket of ER
between
the charged clamp flanked by the conserved K362 in helix 3 and E542 in
helix 12 of ER
(Fig. 8A
). The L886 at
the -1 position of the TRBP LXXLL motif also directly contacted the
hydrophobic regions on the ER
surface. Importantly, the structure
revealed that Ser884 of TRBP points toward the receptor as it had a
similar orientation as the leucine residues (Fig. 2B
). In addition,
TRBP S884 may have close contact with E380 in helix 4 of ER
. This
indicated that E380 of ER
might influence TRBP binding via the S884
residue. Interestingly, the surfaces around S884 in ERß and TRß are
much different than in ER
(Fig. 8
, B and C) (38, 39).
There are more open spaces and the environment has more hydrophobic
character. This may explain why the S884Y mutation resulted in a higher
binding activity of the TRBP peptide for TRß and ERß than for
ER
. Based on the model, it was also understandable why the
negatively charged glutamic acid residue, but not positively charged
arginine residue, at the TRBP S884 position completely abolished
binding for both ER
and ERß (Fig. 6
). Furthermore, when E380 of
ER
was aligned with a number of nuclear receptors, amino acids at
the E380 position of ER
showed conservation within nuclear receptor
subclasses (Fig. 8C
). Class I receptors including AR, GR, MR, and PR
have glutamines (Q) at this position while ER
and ERß have
glutamic acids (E), and class II receptors have lysine (K) or arginines
(R). It is also noteworthy that the hydrophobic character of the
coactivator binding pocket is conserved except for this charged residue
within helix 4. This indicated that each class of receptor might share
a degree of conformational similarity around this position, and that
different coactivators might be able to distinguish among various
receptor subclasses.

View larger version (78K):
[in this window]
[in a new window]
|
Figure 8. The S884 of TRBP Has Close Contact with ER E380
A, The engineered coactivator TRBP peptide bound to ER -LBD is shown
in a molecular surface view. Coordinates of DES/ER -LBD are from
3ERD. The side chains of Leu886, Leu887, Leu890, and Leu891 of TRBP are
shown in green, and the side chain of S884 is shown in
red. The negatively charged (red) E380 in
helix 4, E542 in helix 12, and positively charged (blue)
K362 in helix 3 of ER are also indicated. B, The surface view of
ERß-LBD (1QKM) with TRBP peptide is shown. Side chains of residues in
TRBP are labeled in an identical manner as above. The negatively
charged (red) E332 in helix 4 and positively charged
(blue) K314 in helix 3 of ERß are indicated. Helix 12
of ERß is not shown. C, A similar surface view with TRß-LBD is
shown. TRß (1BSX) structure was obtained from the Protein Data Bank.
The K306 (blue) in helix 4, conserved E457
(red) in helix 12, and K288 (blue) in
helix 3 of TRß are indicated. D, Amino acid alignment of nuclear
receptors within LBD helices 4 and 5. The numbers
indicate the amino acids of ER , ERß, and TRß. The aromatic amino
acids are shown in brown, prolines in
green, threonines and serines in magenta,
positively charged residues in dark blue, negatively
charged residues in red, cystines and methionines in
yellow, glutamines and asparagine in light
blue, and hydrophobic or small residues in gray.
The conserved lysines in helix 3 (ER /K362, ERß/K314, and
TRß/K288) and aligned ER /E380, ERß/E332, and TRßK306 in helix
4 are indicated by arrows.
|
|
To test the hypothesis that TRBP S884 might closely interact with this
charged residue on helix 4, a mutation of ER
at E380 residue was
generated with the substitution of a glycine residue (E380G). The ER
E380G was compared with the wild-type ER
and ERß for its binding
with a number of TRBP S884 mutants (7141242), in which the S884 is
changed to a variety of residues including aromatic, positive, and
negative charged residues (S884E, S884F, S884H, S884K, S884L, S884P,
S884Q, S884W, S884Y). As shown in Fig. 9
, the S884Y and S884F mutants had increased ERß binding, but decreased
ER
binding relative to wild-type (S884), suggesting that the
aromatic side chains of phenylalanine (F) and tyrosine (Y) are
responsible for this selectivity. A mutant bearing tryptophan (W),
which is also aromatic but maybe too bulky in its side chain structure,
bound poorly to both ER
and ERß. However, when the interaction of
the ER
E380G mutant with the TRBP S884 mutants was compared, all
three aromatic residues including tryptophan at S884 resulted in a
dramatic increase in their binding activities, indicating that the
deletion of the E380 side chain was primarily responsible for the
increased interactions of the aromatic residues. These results strongly
suggest that the 884 in TRBP and 380 in ER
may be in close contact.
Hydrophobic leucine (L) and acidic glutamine (Q) at 884 had much less
binding activity than the aromatic residue mutants (Fig. 9
). Positively
charged histidine (H) and lysine (K) in that position in TRBP results
in different binding activities to ER
and ERß. However, E380G of
ER
did not improve binding of either, indicating that the aromatic
structure, rather than charge, may play a major role. A proline (P) at
884 completely abolished the binding. Inasmuch as the 885 position of
TRBP is already a proline in the wild-type protein, another proline
immediately next to it may produce a TRBP peptide that is too rigid to
accommodate an induced fit binding. As expected, the glutamate mutation
(S884E) abolished binding, most likely due to the proximity of other
negatively charged residues nearby on the surface of the LBD. The
precise contact of TRBP S884 with receptors remains to be established.
However, it is clear that each receptor has a unique conformation
surrounding the coactivator binding pocket. The S884 of TRBP
undoubtedly influences the binding selectivity for each of the
receptors.

View larger version (50K):
[in this window]
[in a new window]
|
Figure 9. TRBP Mutants Interact with ER , ER E380G,
and ERß
A TRBP fragment (7141242) containing the LXXLL motif was mutated by
PCR using degenerated primers so that S884 was replaced by a glutamic
acid (E), phenylalanine (F), histidine (H), lysine (K), leucine (L),
proline (P), glutamine (Q), tryptophan (W), or tyrosine (Y). The mutant
proteins were [35S]-methionine-labeled by in
vitro translation. The GST-LBD fusion protein of each of the
nuclear receptors (ER , ER E380G, and ERß) was tested in the
pull-down assays in the presence of 1 µM E2 with the
labeled TRBP wild-type or mutant proteins. Specific nuclear receptors
are indicated on the left. TRBP mutants were labeled and
shown at the bottom of each panel. TRBP S884 is the
wild-type protein. The input lane indicates 20% of the total input.
The amount of GST protein used in the assays for each receptor was
carefully balanced. These samples were quantitated by scintillation
counter, and relative counts are shown as a bar graph in
the bottom panel.
|
|
S884 of TRBP Can Be Phosphorylated in Vitro by
MAPK
The S884 is a proline-directed serine, which is predicted to be a
MAPK phosphorylation site. In vitro phosphorylation studies
with His-tagged TRBP (795931) suggested that S884 can be
phosphorylated by MAPK (ERK2) in vitro (Fig. 10A
). Alanine mutation at S884
significantly reduced, but did not completely abolish, the
phosphorylation, indicating S884 is a major phosphorylation site
for MAPK within this 137-amino acid LXXLL-containing fragment of
TRBP. To evaluate the binding by a phosphorylated TRBP to ER
and
ERß, a synthetic phosphopeptide bearing a phos-S884 was tested. The
results suggested that phosphorylation at S884 of TRBP dramatically
reduced ligand-dependent TRBP interactions with both ER
and ERß
when compared with the wild-type unphosphorylated form, although there
was a significant increase of interactions with the unliganded receptor
(Fig. 10B
). It is currently unknown whether S884 can be phosphorylated
in vivo. However, gene-specific transcriptional
activation, at least in part, may be regulated by
phosphorylation. The phosphorylation at S884 of TRBP is able to
modulate receptor binding in vitro, suggesting the possible
regulatory interactions between coactivator and nuclear receptors, if
such phosphorylation events occur in vivo.

View larger version (34K):
[in this window]
[in a new window]
|
Figure 10. In Vitro Phosphorylation of TRBP at
S884
A, Recombinant his-tagged TRBP (795931) was phosphorylated in
vitro by MAPK as described in Materials and
Methods. After washing, phosphorylated wild-type or S884A
mutant proteins were resolved on SDS-PAGE and detected by
autoradiography. Coomassie staining of His-tagged proteins is shown
below to confirm that equal amounts of protein were
used. B, Phosphorylation of S884 altered binding of TRBP to ER and
ERß. Biotin-labeled TRBP phospho-S884 (pS884) peptide was compared
with the wild-type peptide for the binding of ER and ERß in the
presence or absence of E2 (1 µM). The bound peptides were
quantitated with streptavidin-horseradish peroxidase and
chemiluminescence detection reagents.
|
|
 |
DISCUSSION
|
---|
The coactivator TRBP interacts with nuclear receptors through its
single LXXLL motif in a ligand- as well as AF-2-dependent manner
(30, 31, 32, 33, 34). In this study, we identified the S884 residue at
the -3 position of the TRBP LXXLL motif as a critical residue for
nuclear receptor discrimination. A single S884Y mutation significantly
increased binding to TR, RXR, and ERß and markedly reduced binding to
ER
. In addition, we show that the S884Y mutant not only
differentially interacted with ERß vs. ER
both in
vitro and in vivo, but also displayed functional
differences in ER-mediated transactivation in cells.
The interaction of the LXXLL motif with the nuclear receptor LBD is
well documented. Early mutagenesis studies established the absolute
requirement of the three leucines of the LXXLL motif as well as an
intact AF-2 domain for functional interaction of the coactivator with
the nuclear receptor (1, 9, 10). Subsequent detailed
analysis, including peptide library screens of the LXXLL motif,
revealed that each nuclear receptor has a distinct preference for the
amino acid sequences adjacent to the motif (42, 43, 44, 45, 46, 47).
Interestingly, many LXXLL peptides with hydrophobic residues at the -1
position, resulting in a
LXXLL motif, had higher binding affinity to
nuclear receptors such as TR and ERß (44, 45). This
character is also found in the majority of naturally existing
LXXLL-containing coactivators, which includes most of the motifs of the
three members of the SRC-1 family, both motifs of TRAP220, a number of
motifs in RIP140, and the single motif in both PGC-1 and TRBP.
More interestingly, a proline at the -2 position (P
LXXLL) confers
the highest selectivity for TRß in a peptide library screen
(45). This P
LXXLL motif is found naturally in both TRBP
and TRAP220 and, interestingly, both of these coactivators were
initially identified with high affinity for TR.
Several points were considered for the rationale to identify the amino
acids near the LXXLL motif for residues that may be important for
receptor selectivity. First, small synthetic coactivator peptides can
sometimes yield high binding affinity, but may not reflect
physiological situations in which binding may be regulated and optimal
for in vivo function. We used a natural coactivator TRBP
fragment (528 amino acids) to overcome this limitation. Our data also
suggested that an even longer TRBP fragment (1,350 amino acids, Fig. 7
)
was also able to retain the selectivity. Second, amino acid residues
immediately adjacent to the LXXLL motif were selected for mutation
since they are likely to have close contact with the receptor and thus
may be important for selectivity. Since the LXXLL motif is
-helical
in structure, the -3, -4, +7, and +8 positions are considered to be
the most immediate residues next to the conserved leucines that are
likely to contact the LBD surface. Because a PCR method can be used for
convenient introduction of mutations, we undertook this approach in
which mutations were randomly generated only at these four positions in
a 528-amino acid TRBP fragment containing the LXXLL motif. Among 64
(43) possible nucleotide combinations for each
amino acid, three will be stop codons (TAA, TGA, TAG). In theory,
17.4% (1 - (64 -
3)4)/644) of the
mutations will be stop codons, and a minimum of 22 would need to be
screened to have each residue appear at least once, by chance, at each
of the four positions.
It was expected that most mutations near the motif would reduce the
binding to the receptor since it was most likely that alteration of the
natural structure of the protein would result in deleterious effects on
function. The results did confirm that the majority of the clones
displayed less binding than wild type (Fig. 1
). However, the limited
mutants displaying increased binding provided an opportunity to
identify the residues that may be important. Among these mutants,
clones 6 and 33 had a significant increase in binding to TR and RXR.
Notably, these two clones also selectively favored interaction with
ERß over ER
. Comparison of these clones suggested that aromatic
residues at the -3 position might correlate with the ERß
vs. ER
selectivity, and positive residues at the -4
position (clone 12 and 14) might display selectivity for TRß
vs. RXR. On the other hand, hydrophobic residues at +8
position in clone 11,19, 25, 26, and 27 almost abolished TR, RXR, and
ERß binding, but not ER
binding. These data indicated that the
structural determinants on the surface of TR, RXR, and ERß might
share similarities that differ from ER
.
Crystallographic studies with several nuclear receptors suggested that
most of the residues comprising the coactivator-binding groove are
conserved among receptors. They are nonpolar except for two highly
conserved charged residues, which form the charge clamp. A glutamic
acid residue within helix 12 and an lysine residue in helix 3 have been
demonstrated to be indispensable for LXXLL peptide binding since
mutations at either of these sites abolishes coactivator-peptide
interactions (50). Our modeling studies revealed a residue
near this region, corresponding to E380 in ER
, while variable among
members of the entire nuclear receptor superfamily, is conserved within
receptor subfamilies. The steroid receptors, including AR, GR, MR, and
PR, contain a glutamine residue at this position, whereas ER
and
ERß contain a glutamic acid residue. The class II receptors have
either lysine or arginines at this position (Fig. 8D
). Because the -2
position of the TRBP LXXLL motif is a proline, which breaks the helix
and results in the side chain of S884 to be directed toward helix 4 of
the ER
LBD, it was not surprising that S884 is a critical residue
when the peptide structure of the TRBP LXXLL motif was modeled with the
ER
crystal structure. This structural model prompted us to predict,
and further demonstrate, that the E380 residue closely interacts with
S884 of TRBP. In the case of TRß, RXR, and ERß, this location is
relatively open and composed of mostly hydrophobic residues. This may
explain why a tyrosine substitution at the -3 position increased TRBP
binding to TRß, RXR, and ERß but not to ER
. Because the side
chain of the S884 residue of TRBP is predicted to be in close proximity
to this variable site in the coactivator binding region of the
nuclear receptor, it is likely that the unique chemical character, as
well as the relative spacing displayed by the variable nuclear receptor
residue, may play a role in TRBP selectivity and discrimination between
various nuclear receptor subfamilies. Interestingly, the S884 residue
can be phosphorylated by MAPK in vitro (Fig. 10A
),
and phosphorylation alters the interaction of TRBP to ER
and ERß
(Fig. 10B
). These data indicate that TRBP, when posttranslationally
modified, may exhibit differential interactions with various nuclear
receptors.
Characterization of the unique requirements for nuclear
receptor-specific coactivator binding may be useful for the design of
peptide antagonists that selectively block coactivator binding. This
may be useful for the development of ER isoform-selective antagonists.
The treatment and prevention of ER-related diseases and disorders among
tissues such as breast, bone, urogenital system, cardiovascular system,
and central nervous system rely on our understanding of ER-
mediated transcriptional regulation (48, 52). ER
and ERß have unique tissue distributions as well as distinct
biological functions. ER
is predominantly expressed in many tissues
including the uterus, mammary gland, bone, brain, liver, heart, kidney,
and pituitary, while ERß mRNA is significant in ovary and prostate
(48, 51). Knockout studies have revealed that phenotype
differences exist between ER
- and ERß-deficient animals, such as
breast tissue development (48). Consistent with the
observation that ER modulator-induced conformation changes on ER
and
ERß are distinct (43, 53, 54), our work provides further
evidence that coactivators might differentially interact with the two
receptors. Thus, a better understanding of ER action, including the
selective activation of ER
and ERß, may be helpful in the
development of such therapeutic agents.
 |
MATERIALS AND METHODS
|
---|
Materials and Plasmid Vectors
The ligands for ER including E2, DES, estriol, genestein, LY
117018 (a raloxifene analog), and 4-hydroxytamoxifen were purchased
from Sigma (St. Louis, MO). ICI 182,780 was purchased from
Tocris (Ballwin, MO). Full-length baculovirous-expressed human ER
and ERß was purchased from Pan Vera (Madison, WI). The N-terminal
biotin-labeled TRBP peptides (878896) with mutations at S884 were
synthesized by Sigma-Genosys (Woodlands, TX). The human
TRBP plasmid used in this study was previously described
(30). The TRBP fragment (7141242) containing the LXXLL
motif was subcloned into pcDNA3 and used for in vitro
translation. Nuclear receptor LBDs were inserted in frame into pGEX
4T-2 (Amersham Pharmacia Biotech, Piscataway, NJ) to
produce the glutathione S-transferase (GST)-LBD fusion
proteins (TRß, RXR, ER
, ER
E380G, and ERß). Full-length human
TRß1, ER
, and ERß were subcloned into pcDNA3
(Invitrogen, San Diego, CA). F2/TRE and 2XERE luciferase
reporters were previously described (30). The
5XGal-luciferase reporter pFR-luc was from Stratagene (La
Jolla, CA). Mammalian two-hybrid plasmid vectors pM (Gal DNA-binding)
and pVP16 were from CLONTECH Laboratories, Inc. (Palo
Alto, CA). GAL-TRBP (795999) mutants S884Y and S884E were produced by
PCR and inserted in frame at the C terminus of GAL4 DNA-binding domain
in the pM vector. The GAL-TRBP (795999) alanine mutant (LA) was
constructed by mutating the N889, L890, and L891 residues of TRBP to
alanine.
Random Mutagenesis of the TRBP LXXLL Motif and Binding Analysis
of Individual Clones
Mutations were randomly introduced at amino acid positions -3,
-4, +7, and +8 of the TRBP LXXLL motif
(LTSPLLVNLLQSDI) using PCR. The
underlined amino acids indicate the positions of the
residues that were randomly mutated. Two degenerate primers were
synthesized and used for PCR, producing random mutations at designated
locations within a 528-amino acid TRBP fragment (7141242). The
primers used were P1: TGTTGGTCAACTTATTGCAGNNNNNNATATCTGCAGGCCAT; and
P2: AATAAGTTGACCAACAATGGNNNNNNTAGCGTGACATCCTT. PCR products that
contained a mixture of all of the different mutations were subcloned
into the pcDNA vector under the control of the bacterial T7 promoter.
The plasmid DNA clones for each mutation clones were separated and
isolated by plasmid minipreps, and individually in vitro
translated and [35S]methionine labeled. The
labeled TRBP proteins carrying a variety of mutations were incubated
with GST-LBD of TRß, RXR, ER
and ERß in a binding assay. The
binding assays were performed at room temperature for 1 h in
binding buffer (20 mM HEPES, pH 7.4, 50
mM NaCl, 75 mM KCl, 1
mM EDTA, 0.05% Triton X-100, 10% glycerol, 1
mM dithiothreitol). Bound proteins were washed
three times with binding buffer and subjected to SDS-PAGE followed by
autoradiography. Equal amounts of the GST-LBD proteins within each
receptor group were used. The signal strength was optimized with the
exposure time of film to obtain the best contrast within each receptor
groups.
Recombinant Protein Binding Assays
The GST fusion nuclear receptor LBDs were produced in
Escherichia coli BL21(DE3) and purified with
glutathione-Sepharose resin (Amersham Pharmacia Biotech).
In vitro binding assays were performed by incubating GST-LBD
resin (15 µl, 24 µg) and
[35S]methionine-labeled, in vitro
translated TRBP mutant proteins (5 µl) produced by rabbit
reticulocyte lysate (Promega Corp., Madison, WI). Proteins
were incubated at room temperature for 1 h in binding buffer (20
mM HEPES, pH 7.4, 50 mM
NaCl, 75 mM KCl, 1 mM EDTA,
0.05% Triton X-100, 10% glycerol, 1 mM
dithiothreitol). Bound proteins were washed three times with binding
buffer and subjected to SDS-PAGE followed by autoradiography or
quantitation using a scintillation counter. For the phosphopeptide
binding assay, GST-LBD resins (15 µl, 24 µg) were incubated with
the biotin-labeled peptides (3 µM, WT:
KDVTLTSPLLVNLLQSDIS; pS884: KDVTLTpSPLLVNLLQSDIS) in the presence or
absence of E2 (1 µM) and washed as described
above. The GST-LBD beads were incubated with
streptavidin-peroxidase (1 U/ml, Roche Molecular Biochemicals, Indianapolis, IN) and washed three times. The
beads were then transferred to the 96-well plate, and bound peptides
were detected by chemiluminescence with ECL detection reagents
(Amersham Pharmacia Biotech).
Peptide Binding Assays
The details of methods used in the peptide binding assay
was as previously described (55). Briefly, white
FluoroNunc 96-well plates were coated overnight with 4 pmol/well of
baculovirous-expressed full-length human ER
or ERß. The
receptor-coated plates were blocked with 7.5% BSA in blocking buffer
TBS (0.1 M Tris-HCl, 0.15 M NaCl, 20
µM diethylenetriamine-pentaacetic acid) at room
temperature for 1 h. The plates were then washed three times with
0.1% Triton X-100 in TBS (TBST). Biotin-labeled TRBP peptides (6.6
nM) carrying mutations at S884 were preincubated with
europium-conjugated streptavidin (0.83 µg/ml) on ice for 30 min.
Peptide-europium conjugates (120 µl) were diluted with DELFIA assay
buffer (Perkin-Elmer Corp., Gaithersburg, MD) into
10 ml and applied to the 96-well plate with 90 µl/well. E2 was then
added at appropriate concentrations to each well, and plates were
incubated for 1.5 h at room temperature followed by five washes
with TBST. The signal was detected by adding 100 µl of DELFIA
Enhancement Solution (Perkin-Elmer Corp.) with 5 min of
gentle shaking followed by analysis using a Wallac, Inc.
Victor II plate reader. The peptides used in this assay are as
follows. WT: KDVTLTSPLLVNLLQSDIS; S884R: KDVTLTRPLLVNLLQSDIS; S884Y:
KDVTLTYPLLVNLLQSDIS; S884E: KDVTLTEPLLVNLLQSDIS; LA:
KDVTLTEPLLVNAAQSDIS.
Cell Culture and Transient Transfection
CV-1 cells were maintained in DMEM supplemented with 10% FBS
and 0.1 µg/µl penicillin/streptomycin in 5%
CO2 at 37 C. Cells were plated in 24-well plates
for 2 d before transfection. CV-1 cells were transfected using
lipofect- AMINE reagent according to the manufacturers protocol
(Life Technologies, Inc., Gaithersburg, MD). Cells were
incubated in fresh serum-free medium containing 100 µM of
ligand for 1624 h after transfection. Total amounts of DNA for each
well were balanced by adding vector DNA pcDNA3
(Invitrogen). Relative luciferase activities were measured
and shown as means of triplicate transfections ± SE
values.
Crystal Structure Modeling with TRBP Peptide
TRBP peptide structure (882895, LTSPLLVNLLQSDI)
was computationally engineered based on the backbone of the PPAR
AF-2 helix (SLHPLLQEIYKLDL) (2PRG) (37). The
AF-2 domains were shown to contact the LXXLL-binding pocket and
structurally overlap with the LXXLL helices (1, 10, 36).
In addition, the AF-2 helices in a number of receptors align with the
coactivator LXXLL motifs (37). Since the PPAR
AF-2 has
a leucine at the -1 and a proline at the -2 positions, the backbone
of PPAR
AF-2 resembles the backbone of TRBP LXXLL peptide near the
-3 position. Amino acid side chains were computationally engineered
using the QUANTA program. The three hydrophobic leucines of the
engineered TRBP peptide were aligned with the three leucines of GRIP-1
peptide in the three-dimensional crystal structure of ER
or TRß.
In the case of ERß, the leucines of the TRBP LXXLL were aligned with
the corresponding hydrophobic residues of helix 12 in ERß.
Coordinates of ER
/DES/GRIP-1 (3ERD) (36),
ERß/genestein (1QKM), and TRß/GRIP-1 (1BSX) were obtained from the
Protein Data Bank (38, 39).
In Vitro Kinase Phosphorylation
In vitro phosphorylation of recombinant His-tagged
TRBP (795931) by MAPK was assayed using the SigmaTECT Protein Kinase
Assay buffer system from Promega Corp. with modifications.
Briefly, MAPK (ERK2, New England Biolabs, Inc., Beverly,
MA) was incubated in supplied buffer system with
32P-
-ATP and His-tagged wild-type TRBP
(795931) or TRBP S884A (795931) as substrates. Labeled His-tagged
protein beads were washed, and the proteins were resolved by SDS-PAGE
followed by autoradiography.
 |
ACKNOWLEDGMENTS
|
---|
We thank Gary Krishnan for the human ERß plasmid, Faming Zhang
for crystal structure modeling, and Andrew G. Geiser for editing of the
manuscript.
 |
FOOTNOTES
|
---|
This work was supported by Lilly Postdoctoral Research
Fellowships.
Abbreviations: ACTR, Activator of thyroid receptor; AF-2,
activation function 2; AIB, amplified in breast cancer; ASC-2,
activating signal cointegrator-2; CBP, cAMP response element binding
protein binding protein; CIA, coactivator independent of AF-2 function;
CoAA, coactivator activator; DES, diethylstilbestrol; DRIP,
vitamin D receptor-interacting protein; GRIP, GR-interacting
protein; GST, glutathione-S-transferase; LBD,
ligand-binding domain; NcoA, nuclear receptor coactivator; NRC, nuclear
receptor cointegrator; PBP, PPAR
binding protein; PGC-1, PPAR
coactivator-1; RAC-3, receptor associate coactivator 3; RRM, RNA
recognition motif; SRC, steroid receptor coactivator; TIF-2,
transcriptional intermediary factor 2; TRAP, TR associate protein;
TRBP, TR binding protein.
Received for publication May 17, 2001.
Accepted for publication September 14, 2001.
 |
REFERENCES
|
---|
-
McKenna NJ, Lanz RB, OMalley BW 1999 Nuclear receptor
coactivators: cellular and molecular biology. Endocr Rev 20:321344[Abstract/Free Full Text]
-
Mangelsdorf DJ, Evans RM 1995 The RXR heterodimers and orphan
receptors. Cell 83:841850[Medline]
-
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G,
Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The
nuclear receptor superfamily: the second decade. Cell 83:835839[Medline]
-
Tsai MJ, OMalley BW 1994 Molecular mechanisms of action of
steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451486[CrossRef][Medline]
-
Burris TP 2000 The nuclear receptor superfamily. In: Burris
TP, McCabe ERB, eds. Nuclear receptors and genetic disease. New York:
Academic Press; 157
-
Xu L, Glass CK, Rosenfeld MG 1999 Coactivator and corepressor
complexes in nuclear receptor function. Curr Opin Genet Dev 9:140147[CrossRef][Medline]
-
Hu X, Lazar, MA 1999 The CoRNR motif controls the recruitment
of corepressors by nuclear hormone receptors. Nature 402:9396[CrossRef][Medline]
-
Chen JD, Li H 1998 Coactivation and corepression in
transcriptional regulation by steroid/nuclear hormone receptors. Crit
Rev Eukaryot Gene Expr 8:169190[Medline]
-
McInerney EM, Rose DW, Rlynn SE, Westin S, Mullen TM,
Drones A, Inostroza J, Torchia J, Nolte RT, Assamunt N, Milburn MV,
Glass CK, Rosenfeld MG 1998 Determinants of coactivator LXXLL motif
specificity in nuclear receptor transcriptional activation. Genes Dev 12:33573368[Abstract/Free Full Text]
-
Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature
motif in transcriptional coactivators mediates binding to nuclear
receptors. Nature 387:733736[CrossRef][Medline]
-
Leo C, Chen JD 2000 The SRC family of nuclear receptor
coactivators. Gene 245:111[CrossRef][Medline]
-
Onate SA, Tsai SY, Tsai MJ, OMalley BW 1995 Sequence and
characterization of a coactivator for the steroid receptor superfamily.
Science 270:13541357[Abstract]
-
Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR 1996 GRIP1, a novel mouse protein that serves as a transcriptional
coactivator in yeast for the hormone binding domain of steroid
receptors. Proc Natl Acad Sci USA 93:49484952[Abstract/Free Full Text]
-
Hong H, Kohli K, Garabedian MJ, Stallcup MR 1997 GRIP1, a
transcriptional coactivator for the AF2 transactivation domain of
steroid, thyroid, retinoid and vitamin D receptors. Mol Cell Biol 17:27352744[Abstract]
-
Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent
activation function of AF-2 of nuclear receptors. EMBO J 15:36673675[Abstract]
-
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan
XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS 1997 AIB1, a steroid
receptor coactivator amplified in breast and ovarian cancer. Science 277:965968[Abstract/Free Full Text]
-
Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L,
Privalsky ML, Nakatani Y, Evans RM 1997 Nuclear receptor coactivator
ACTR is a novel histone acetyltransferase and forms a multimeric
activation complex with P/CAF and CBP/p300. Cell 90:569580[Medline]
-
Li H, Gomes PJ, Chen JD 1997 RAC3, a steroid/nuclear
receptor-associated coactivator that is related to SRC-1 and TIF-2.
Proc Natl Acad Sci USA 94:84798484[Abstract/Free Full Text]
-
Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW 1997 TRAM-1, a novel 160 kDa thyroid hormone receptor activator molecule,
exhibits distinct properties from steroid receptor coactivator-1.
J Biol Chem 272:2762927634[Abstract/Free Full Text]
-
Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK,
Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and
mediates nuclear-receptor function. Nature 387:677684[CrossRef][Medline]
-
Takeshita A, Yen PM, Misiti S, Cardona GR, Liu Y, Chin WW 1996 Molecular cloning and properties of a full-length putative thyroid
hormone receptor coactivator. Endocrinology 137:35943597[Abstract]
-
Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP,
Brennan RG, Roberts SG, Green MR, Goodman RH 1994 Nuclear protein CBP
is a coactivator for the transcription factor CREB. Nature 370:223226[CrossRef][Medline]
-
Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM 1998 A cold-inducible coactivator of nuclear receptors linked to
adaptive thermogenesis. Cell 20:829839
-
Knutti D, Kaul A, Kralli A 2000 A tissue-specific coactivator
of steroid receptors, identified in a functional genetic screen. Mol
Cell Biol 20:24112422[Abstract/Free Full Text]
-
Sauve F, McBroom LDB, Gallant J, Moraitis AN, Labrie F,
Giguere V 2001 CIA, a novel estrogen receptor coactivator with a
bifunctional nuclear receptor interacting determinant. Mol Cell Biol 21:343353[Abstract/Free Full Text]
-
Joyeux A, Cavailles V, Balaguer P, Nocolas JC 1997 RIP 140
enhances nuclear receptor-dependent transcription in vivo in
yeast. Mol Endocrinol 11:193202[Abstract/Free Full Text]
-
Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M,
Naar AM, Erdjument-Bromage H, Tempst P, Freedman LP 1999 Ligand-dependent transcription activation by nuclear receptors requires
the DRIP complex. Nature 398:824828[CrossRef][Medline]
-
Ito M, Yuan, CX, Malik S, Gu W, Fondell JD, Yamamura S, Fu ZY,
Zhang X, Qin J, Roeder RG 1999 Identity between TRAP and SMCC complexes
indicates novel pathways for the function of nuclear receptors and
diverse mammalian activators. Mol Cell 3:361370[Medline]
-
Zhu Y, Qi C, Jain S, Rao MS, Reddy JK 1997 Isolation and
characterization of PBP, a protein that interacts with peroxisome
proliferator-activated receptor. J Biol Chem 272:2550025506[Abstract/Free Full Text]
-
Ko L, Cardona GR, Chin WW 2000 Thyroid hormone
receptor-binding protein, an LXXLL motif-containing protein, functions
as a general coactivator. Proc Natl Acad Sci USA 97:62126217[Abstract/Free Full Text]
-
Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK,
Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun BH, Cheong JH, Lee
YC, Meltzer PS, Lee JW 1999 A nuclear factor, ASC-2, as a
cancer-amplified transcriptional coactivator essential for
ligand-dependent transactivation by nuclear receptors in
vivo. J Biol Chem 274:3428334293[Abstract/Free Full Text]
-
Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson JA 2000 Cloning and characterization of RAP250, a novel nuclear receptor
coactivator. J Biol Chem 275:53085317[Abstract/Free Full Text]
-
Mahajan MA, Samuels HH 2000 A new family of nuclear receptor
coregulators that integrates nuclear receptor signaling through
CREB-binding protein. Mol Cell Biol 20:50485063[Abstract/Free Full Text]
-
Zhu Y, Kan L, Qi C, Yashpal S, Kanwar YS, Anjana V, Yeldandi
AV, Rao MS, Reddy JK 2000 Isolation and characterization of peroxisome
proliferator-activated receptor (PPAR) interacting protein (PRIP) as a
coactivator for PPAR. J Biol Chem 275:1351013516[Abstract/Free Full Text]
-
Guan XY, Xu J, Anzick SL, Zhang H, Trent JM, Meltzer PS 1996 Hybrid selection of transcribed sequences from microdissected DNA:
isolation of genes within amplified region at 20q11q13.2 in breast
cancer. Cancer Res 56:34463450[Abstract]
-
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA,
Greene GL 1998 The structural basis of estrogen receptor/coactivator
recognition and the antagonism of this interaction by tamoxifen. Cell 95:927937[Medline]
-
Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T,
Engstrom O, Ohman L, Greene GL, Gustafsson J-A, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor.
Nature 389:753758[CrossRef][Medline]
-
Pike ACW, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG,
Engstrom O, Ljunggren J, Gustafsson J-A, Carlquist M 1999 Structure of
the ligand-binding domain of oestrogen receptor ß in the presence of
a partial agonist and a full agonist. EMBO J 18:46084618[Abstract/Free Full Text]
-
Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ,
Baxter JD, Fletterick, RJ, Yamamoto, KR 1998 Structure and specificity
of nuclear receptor-coactivator interactions. Gene Dev 12:33433356[Abstract/Free Full Text]
-
Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L,
Berkenstam A 1998 Crystal structure of the ligand binding domain of the
human nuclear receptor PPAR
. J Biol Chem 273:3110831112[Abstract/Free Full Text]
-
Pike AC, Brzozowski AM, Walton J, Hubbard RE, Thorsell A, Li
Y, Gustafsson J, Carlquist M 2001 Structural insights into the mode of
action of a pure antiestrogen. Structure 9:145153[Medline]
-
Ren Y, Behre E, Ren Z, Zhang J, Wang Q, Fondell JD 2000 Specific structural motifs determine TRAP220 interactions with nuclear
hormone receptors. Mol Cell Biol 20:54335446[Abstract/Free Full Text]
-
Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB,
Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM 1999 Estrogen receptor (ER) modulators each induce distinct
conformational changes in ER
and ER ß. Proc Natl Acad Sci USA 96:39994004[Abstract/Free Full Text]
-
Chang C-Y, Norris JD, Gron H, Paige LA, Hamilton PT, Kenan DJ,
Fowlkes D, McDonnell DP 1999 Dissection of the LXXLL nuclear
receptor-coactivator interaction motif using combinatorial peptide
libraries: discovery of peptide antagonists of estrogen receptors
and ß. Mol Cell Biol 19:82268239[Abstract/Free Full Text]
-
Northrop JP, Nguyen D, Piplani S, Olivan SE, Kwan STS, Go NF,
Hart CP, Schatz P 2000 Selection of estrogen receptor ß and thyroid
hormone receptor ß specific coactivator mimetic peptides using
recombinant peptide libraries. Mol Endocrinol 14:605622[Abstract/Free Full Text]
-
Heery DM, Hoare S, Hussain S, Parker MG, Sheppard H 2001 Core
LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define
affinity and selectivity for steroid and retinoid receptors. J
Biol Chem 276:66956702[Abstract/Free Full Text]
-
Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan
D, Hamilton PT, Fowlkes DM, McDonnell DP 1999 Peptide antagonists of
the human estrogen receptor. Science 285:744746[Abstract/Free Full Text]
-
Couse JF, Korach KS 1999 Estrogen receptor null mice: what
have we learned and where will they lead us? Endocr Rev 20:358417[Abstract/Free Full Text]
-
Iwasaki T, Chin WW, Ko L 2001 Identification and
characterization of an RRM-containing coactivator activator (CoAA) as
TRBP-interacting protein as its splice variant as a coactivator
modulator (CoAM). J Biol Chem 276:3337533383[Abstract/Free Full Text]
-
Henttu PMA, Kalkhoven E, Parker MG 1997 AF-2 activity and
recruitment of steroid receptor coactivator 1 to the estrogen receptor
depend on a lysine residue conserved in nuclear receptors. Mol Cell
Biol 17:18321839[Abstract]
-
Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J,
Nilsson S, Gustafsson J-A 1997 Comparison of the ligand binding
specificity and transcript tissue distribution of estrogen receptor
and ß. Endocrinology 138:863870[Abstract/Free Full Text]
-
Nilsson S, Kuiper G, Gustafsson JA 1998 ERß, a novel
estrogen receptor offers the potential for new drug development. Trends
Endocrinol Metab 9:387395[CrossRef]
-
Warnmark A, Almlof T, Leers J, Gustafsson JA, Treuter E 2001 Differential recruitment of the mammalian mediator subunit TRAP220 by
estrogen receptors ER
and ERß. J Biol Chem [epub ahead of
print]
-
Schapira M, Raaka BM, Samuels HH, Abagyan R 2000 Rational
discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad
Sci USA 97:10081013[Abstract/Free Full Text]
-
Bramlett KS, Wu Y, Burris TP 2001 Ligands specify coactivator
nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol
Endocrinol 15:909922[Abstract/Free Full Text]